BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) have been demonstrated impressive efficacy in patients with advanced stage NSCLC harboring BRAF V600E mutation. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.